Compare AbbVie Inc (ABBV) vs Applovin Corporation (APP) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

AppLovin (APP) trades at $543.79, up 3.17% with strong technical momentum and bullish analyst sentiment. The stock demonstrates exceptional profitability with 64.29% net income margins and consistent earnings beats. Recent Q1 2026 results showed $3.56 EPS beating expectations, while technical indicators signal bullish momentum with key resistance at $554. The company's AI-powered advertising platform drives robust revenue growth, with 2026 revenue projected at $6.2 billion.

AppLovin presents compelling growth potential with 88% analyst buy ratings and $644.09 consensus price target, offering 18% upside. However, premium valuations (P/E 47.29, P/S 30.03) and competitive pressures in mobile advertising represent key risks. The upcoming Q2 2026 earnings on August 5th will be crucial for validating the AI growth narrative and sustaining current momentum.